newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

  • AEON Biopharma announced the Compensation Committee approved inducement awards for new Chief Financial Officer John Bencich on April 2, 2026.
  • The Committee granted Bencich 754,717 restricted stock units (RSUs) that vest 25% annually on March 9 starting from his employment start date.
  • The Committee also granted 235,849 performance-based restricted stock units (PSUs) under the 2025 Employment Inducement Incentive Award Plan.
  • PSU vesting begins six months after NYSE American notifies the Company of regained compliance with listing standards, with subsequent 25% tranches vesting on the first three anniversaries of that date.
  • The equity awards were granted as inducement material for Bencich's employment in accordance with Section 711 of the NYSE American LLC Company Guide.
  • AEON is advancing ABP-450 as a biosimilar to BOTOX to achieve full-label U.S. market entry for therapeutic neurotoxin indications.
  • ABP-450 is manufactured by Daewoong Pharmaceutical in an FDA-authorized facility and holds existing biosimilar approvals in India, Mexico, and the Philippines.
  • AEON holds exclusive development and distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, and other international territories.
  • Forward-looking statements highlight risks including AEON's ability to meet continued stock exchange listing standards and regain compliance with NYSE American requirements.